In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Bio-Techne trades 39% above a high-confidence fair value of $35.41, indicating potential overvaluation. Monte Carlo analysis shows high downside risk with median valuation well below current price and significant volatility. Strong liquidity contrasts weak profitability and growth, signaling fundamental challenges amid price premium.